Atlas Three · Medicine · Cardiovascular

Statins

HMG-CoA reductase inhibitors — the most widely prescribed cardiovascular drug class and the cornerstone of LDL-C reduction and atherosclerosis prevention.

30–55% LDL-C reduction. 22% MACE reduction per 1 mmol/L LDL-C fall. 170,000 participants across 26 trials. The lower-the-better principle.

4Landmark Trials
22%MACE ↓ per 1 mmol/L
30–55%LDL-C ↓
6Key Agents
Medicine Atlas · Cardiovascular · HMG-CoA Reductase Inhibitors

Statins

Class: HMG-CoA reductase inhibitor  |  Route: Oral  |  Status: First-line lipid-lowering, primary and secondary prevention of ASCVD

Competitive inhibitors of HMG-CoA reductase — the rate-limiting enzyme in the mevalonate pathway. Reduce hepatic cholesterol synthesis → SREBP-2 activation → LDL receptor upregulation → plasma LDL-C falls 30–55%. Landmark RCTs across five decades demonstrate consistent 20–35% relative risk reductions in MACE. The Cholesterol Treatment Trialists meta-analysis (170,000 participants, 26 trials) established a linear dose-response: 22% MACE reduction per 1 mmol/L LDL-C fall.

HMG-CoA reductase inhibitors statin therapy

Overview

Statins are HMG-CoA reductase inhibitors — competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in the mevalonate pathway that produces cholesterol in the liver. By blocking this enzyme, statins reduce hepatic cholesterol synthesis, causing compensatory upregulation of LDL receptors on hepatocytes, which clears LDL-C from plasma. Net result: 30–55% reduction in plasma LDL-C depending on agent and dose.

They are the most widely prescribed cardiovascular drugs globally, with one of the strongest evidence bases in clinical pharmacology. Landmark trials across five decades have consistently demonstrated that lowering LDL-C with statins reduces major adverse cardiovascular events (MACE: MI, stroke, cardiovascular death) in both primary prevention (no prior CV disease) and secondary prevention (established ASCVD).

The Cholesterol Treatment Trialists (CTT) meta-analysis (2010) — pooling 26 trials and 170,000 participants — found a 22% reduction in MACE per 1 mmol/L (~39 mg/dL) reduction in LDL-C, a dose-response relationship that is linear and consistent across all risk groups.

Mechanism of Action

HMG-CoA Reductase Inhibition — The Mevalonate Pathway

  Acetyl-CoA
      │
      ▼
   HMG-CoA  ──────────────────────────────────────────────
      │                                                    │
      │  HMG-CoA reductase  ← STATIN BINDS HERE           │
      │  (rate-limiting step)                              │
      ▼                                                   (blocked)
  Mevalonate
      │
      ▼
  Isoprenoids → Cholesterol → bile acids, steroid hormones
              → Dolichols, Ubiquinone (CoQ10)
              → Ras/Rho prenylation (pleiotropic effects here)

Statins contain a structural mimic of the HMG-CoA substrate that occupies the active site with nanomolar affinity. Competitive inhibition at this step:

  1. Reduces intracellular cholesterol in hepatocytes
  2. Activates SREBP-2 — the cholesterol sensor transcription factor
  3. SREBP-2 drives transcription of LDLR — LDL receptor density on hepatocytes increases
  4. Increased LDL-R captures LDL particles from plasma → plasma LDL-C falls
  5. VLDL secretion also mildly reduced; HDL-C increases modestly (~5–10%)

Pleiotropic Effects

Statins produce benefits at the tissue and system level beyond LDL-C reduction, likely through inhibition of isoprenoid intermediates (Ras/Rho prenylation):

Plaque stabilization

Reduce macrophage infiltration, upregulate eNOS, stabilize the fibrous cap — reducing rupture risk even before significant plaque volume regression

Anti-inflammatory

Reduced hsCRP; modulation of NF-κB and cytokine production — independent of LDL-C changes

Endothelial function

Improved nitric oxide bioavailability → vasodilation; reduced endothelial dysfunction — an early step in atherogenesis

Antithrombotic

Reduced tissue factor expression; attenuated platelet aggregation — reduces thrombotic risk at the plaque surface

Whether pleiotropic effects confer clinical benefit independent of LDL-C lowering remains debated; the CTT meta-analysis supports LDL-C reduction as the dominant mechanism.

Indications

Per the 2018 AHA/ACC Guideline on Management of Blood Cholesterol:

Patient GroupRecommendationStatin Intensity
Clinical ASCVD (secondary prevention) High-intensity statin Atorvastatin 40–80 mg or rosuvastatin 20–40 mg
LDL ≥ 190 mg/dL (familial hypercholesterolemia) High-intensity ± ezetimibe ± PCSK9i Atorvastatin 40–80 mg or rosuvastatin 20–40 mg
Diabetes + age 40–75, LDL 70–189 mg/dL Moderate-intensity statin Atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg
10-yr ASCVD risk ≥ 7.5%, LDL ≥ 70 mg/dL Moderate-intensity (discuss risk) As above; shared decision-making with risk calculator
Lower risk (primary prevention) Shared decision-making Based on 10-yr ASCVD risk calculation and patient preference

Key Agents

AgentLDL-C ↓ (max dose)Half-lifeMetabolismNotes
Rosuvastatin (Crestor) ~55% (40 mg) · High ~19 h Minimal CYP450; renal/fecal Hydrophilic; lowest drug-drug interaction risk
Atorvastatin (Lipitor) ~50% (80 mg) · High ~14 h (active metabolites longer) CYP3A4 Most widely prescribed; both primary and secondary prevention trials
Simvastatin (Zocor) ~38% (40 mg) · Moderate ~2 h (prodrug) CYP3A4 HPS trial; dose-limited — 80 mg associated with myopathy risk
Pravastatin (Pravachol) ~28% (40 mg) · Moderate ~2 h Not CYP metabolized; renal Lowest drug-drug interaction; WOSCOPS trial; preferred in complex regimens
Pitavastatin ~32% (4 mg) · Moderate ~11 h Minimal CYP Preferred in patients on complex multi-drug regimens; no major interactions
Fluvastatin ~24% (80 mg) · Low–Moderate ~3 h CYP2C9 Weaker; less commonly used

Intensity Classification

High Intensity

≥50% LDL-C reduction expected

Atorvastatin 40–80 mg
Rosuvastatin 20–40 mg

Moderate Intensity

30–50% LDL-C reduction

Atorvastatin 10–20 mg
Rosuvastatin 5–10 mg
Simvastatin 20–40 mg
Pravastatin 40–80 mg

Low Intensity

<30% LDL-C reduction

Simvastatin 10 mg
Pravastatin 10–20 mg

Evidence Base — Landmark Trials

TrialDrugPopulationKey Result
4S (1994) Simvastatin 20–40 mg 4,444 patients with CAD, LDL 213 mg/dL mean 30% ↓ all-cause mortality; 34% ↓ MACE. First trial to show statins reduce mortality.
WOSCOPS (1995) Pravastatin 40 mg 6,595 men, no prior MI, hypercholesterolemia 31% ↓ non-fatal MI + coronary death. Landmark primary prevention RCT.
HPS (2002) Simvastatin 40 mg 20,536 high-risk patients, LDL ≥ 116 mg/dL 25% ↓ MACE across all LDL levels — including those with LDL <116 mg/dL, establishing benefit regardless of baseline LDL.
CTT meta-analysis (2010) Multiple statins 170,000 participants across 26 randomised trials 22% ↓ MACE per 1 mmol/L LDL-C reduction; linear dose-response with no safety floor identified.

The Lower-the-Better Principle: CTT data support a continuous, log-linear relationship — every additional 1 mmol/L (~39 mg/dL) reduction in LDL-C reduces MACE by ~22%, with no lower safety threshold identified in statin trials. This underpins the 2018 guideline principle of maximizing statin intensity in high-risk patients and combining with ezetimibe or PCSK9 inhibitors when targets are not met.

Side Effects

  • Myopathy / statin-associated muscle symptoms (SAMS) — most common reason for discontinuation. Spectrum: myalgia (no CK elevation) → myositis (CK elevation) → rhabdomyolysis (CK >10× ULN + renal injury; rare, ~0.1%). Risk increased by high-dose statins, CYP3A4 inhibitors (with atorvastatin/simvastatin), hypothyroidism, renal insufficiency.
  • Liver enzyme elevation — transaminase rises >3× ULN in ~0.1–1%; usually transient and dose-dependent; routine monitoring not required in the absence of symptoms.
  • New-onset diabetes — moderate increased risk (~10–15% relative; smaller absolute risk); more prevalent with high-intensity statins in pre-diabetic patients. Clinical cardiovascular benefits overwhelmingly exceed this risk in at-risk populations.
  • Cognitive effects — rare case reports; not confirmed in large RCTs; not considered a contraindication.
  • Teratogenicity — contraindicated in pregnancy and breastfeeding; cholesterol is essential for fetal development (stop before conception where possible).

Connections

Acts on Cardiovascular System Used with Beta-blockers Targets HMG-CoA Reductase (entry pending)

References